A wave of fresh clinical data is reshaping how doctors fight esophageal cancer. In a study led by Professor Huang Jing, a dual‑targeted immunotherapy (cadilenimab) paired with standard chemotherapy drugs (paclitaxel and cisplatin) produced an 81% tumor‑shrinkage rate and nearly 98% disease‑control in patients with advanced, inoperable disease. Even more exciting, researchers discovered that tiny chemical tags on patients’ blood DNA could predict who would respond best, offering a non‑invasive “chemo‑response test.” Meanwhile, a chemo‑free regimen that mixes a blood‑vessel blocker (anlotinib) with a new immune drug (benmelstomalide) achieved a 56% response rate and kept tumors at bay for over a year. The breakthrough doesn’t stop there: China’s first bispecific antibody‑drug conjugate, iza‑bren, showed promising survival numbers in patients who had already tried other treatments, and a large Phase III trial confirmed its benefit, positioning it as a future frontline option. Scientists also identified genetic clues—like NOTCH1 mutations—that signal a better chance of long‑term survival with certain immunotherapies. Follow‑up strategies are proving vital: a year‑long maintenance dose of atezolizumab after chemoradiation boosted complete response rates, and a newer “NICE” pre‑surgery regimen outperformed the older CROSS protocol, delivering higher three‑year survival. Together, these advances suggest that smarter drug combos, blood‑based markers, and tailored post‑treatment plans could turn a once‑fatal disease into a manageable condition.
Read more